An inventory of the status quo of the new crown pneumonia intersurergen stem cell therapy.

Since the outbreak of new coronary pneumonia, stem cells, especially mesoplasm stem cells (MSCs), have been increasingly used in the treatment of serious and critical diseases.
, the United States, the United Kingdom, Japan, South Korea and Israel have also approved stem cells for the treatment of new coronary pneumonia clinical research, stem cells have become an indispensable anti-epidemic innovative therapy.
between mechanisms of action (MSC) is a kind of multi-potential tissue stem cells with multi-way differentiation and self-renewal ability.
Numerous studies have confirmed that MSC has powerful anti-inflammatory and immunomodulation functions that reduce acute and chronic lung damage and inflammatory factor secretion levels by inhibiting lung-soaked immune cells, reducing the risk of cytokine storms, as well as by secreting hepatocellular growth factors (HGFs) Such factors promote the repair of the alps-epiderr barrier in acute respiratory distress syndrome (ARDS) pulmonary injury, enhance the ability to repair lung tissue damage, and further reduce the level of pulmonary fibrosis;
the current research status is based on the above advantages, more and more research institutions began to start on MSC treatment COVID-19 project, there have been a number of use of MSC treatment COVID-19 clinical trials, there are currently research results, MSC on the new coronary pneumonia, especially for the treatment of serious patients have a better effect.
The domestic has completed more than 200 stem cell treatments in Wuhan in April this year, from the results, clinical treatment safety is good: patients with improved lung lesions, improved respiratory function;
In addition, a recent study published in the Lancet sub-issue of EClinical Medicine using fat-based intersurge stem cells (AT-MSC) to treat 13 patients with severe corona who needed mechanical breathing also showed that most patients received good clinical improvements and found no adverse events associated with cell therapy.
After the first drug use, the mid-range follow-up time was 16 days, 9 patients (70%) were observed to have clinical improvement, 7 patients were discharged from the hospital, 4 patients continued to be intested (2 cases of improved breathing and radiology parameters, 2 cases of stable condition), and the team compared clinical progress and patient mortality from 70-85% to 15% by comparing similar cases in the intensive care unit (ICU).
clinical progress so far, there are 21 clinical research projects on "new coronavirus pneumonia" related to "stem cells" registered in the China Clinical Trial Registry (ChiCTR), 18 of which are clearly related to MSC.
research institutions mainly in hospitals, the vast majority of research is still in the exploratory research or pre-test stage.
Of the 15 studies that obtained informed consent and ethical review, Chinese the clinical study of the treatment of new coronavirus pneumonia (COVID-19) patients with human-filled stem cells at the Fifth Medical Center of the People's Liberation Army General Hospital has entered clinical phase II;
Internationally, according to relevant statistics, the FDA has approved from many countries MSC treatment of new coronary pneumonia caused by ARDS clinical trial applications, involving umbilical cord, fat, placenta and other sources of human-filled stem cells, at the same time, both self-contained, foreign sources.
These studies are basically in Phase II and above and are active, of which more than half (4) are carried out by two research and development pharmaceutical companies, and the other three are carried out by three well-known medical research institutions, involving a total of five filing units.
noteworthy that clinical trials in two varieties have progressed rapidly and have entered phase III.
, which is currently making rapid progress, such as Athersys, has been approved to launch a Phase II/III critical clinical MACOVIA to evaluate the treatment of moderate to severe ARDS caused by new coronary pneumonia in the intersystem-charged stem cell MultiStem of his alloglyogenic bone marrow.
In the I/II study, the Multistem treatment group had a lower mortality rate and more ventilator-free days (VFD: 12.9 days vs 9.2 days) and more intensive care unit (ICU) days (10.3 days vs 8.1 days) during the 28-day treatment period compared to the placebo group.
, 45 percent of patients in the MultiStem treatment group were removed from the ventilator within seven days, while the placebo group was only 20 percent.
based on the above positive data, the FDA recently granted MultiStem Fast Track Qualification (FTD) for the treatment of ARDS.
the same time, Australia's Mesoblast's experimental isotropic charge stem cell Ryoncil (remestemcel-L) has also attracted attention.
Ryoncil, which had been successful in Phase III clinical trials for children treating steroid incurable acute grafts (SR-aGVHD), has been approved for new coronary pneumonia, with two intravenous infusions of Ryoncil yielding 83% survival in a study of moderate to severe ARDS patients with COVID-19.
On the Israeli side, AlloRx Stem Cells, a new stem cell drug for new coronary pneumonia, has filed an IND application with the FDA, and Israel's Pluristem Therapeutics has treated six patients with COVID-19 severe illnesses using intersurge-like cells derived from human placental heterogens, all surviving and recovering.
Japan, Healios is already conducting an evaluation trial of the stem cell product HLCM051 for ARDS, and clinical data have demonstrated the safety and effectiveness of HLCM051 in pneumonia-induced ARDS patients.
new crown outbreak is the largest global health emergency since the beginning of the 20th century, the current global new crown confirmed cases have exceeded 18.54 million cases, a cumulative death of more than 700,000 cases.
pharmaceutical academic institutions, medical institutions, pharmaceutical companies and so on have invested in efforts to combat the epidemic, not only stem cell research, vaccines, antibodies, Traditional Chinese medicine ... All areas are contributing their own strength, I believe that pay will have a harvest.
Tandese, "as long as the global and national levels come together, the future remains in our hands."
.